The invention relates to a process of process of producing a fermentation product, comprising: liquefying a starch-containing material to dextrins with an alpha-amylase in the presence of an asparaginase and/or an amino acid oxidase; saccharifying the dextrins to a sugar with a glucoamylase; and fermenting the sugar using a fermenting organism.

Disclosed are compositions containing exosomes loaded with arginase or arginase chimeras for treating hyperammonemia due to arginase deficiency, and methods for treating hyperammonemia by administering compositions containing exosomes loaded with arginase or arginase chimeras.

A method of treating Arginase 1 (ARG1) deficiency (ARG1-D) in a subject, comprising administering a pegzilarginase to the subject, wherein the pegzilarginase is a pegylated human arginase 1 comprising a cobalt metal cofactor, and wherein the pegzilarginase is administered weekly at a dose of from about 0.05 mg/kg to about 0.2 mg/kg.

Disclosed herein are novel compounds, pharmaceutical compositions comprising such compounds and related methods of their use. The compounds described herein are useful, e.g., as liposomal delivery vehicles to facilitate the delivery of encapsulated polynucleotides to target cells and subsequent transfection of said target cells, and in certain embodiments are characterized as having one or more properties that afford such compounds advantages relative to other similarly classified lipids.

The present invention relates to novel polypeptides derived from Arginase 2 (ARG2), polynucleotides encoding said polypeptides, and compositions comprising said polypeptides or polynucleotides. The invention also concerns uses of said polypeptides, polynucleotides and compositions.

Described are methods for producing recombinant Arginase, such as PEGylated, cobalt-substituted recombinant human Arginase 1. Also described are pharmaceutical compositions comprising such recombinant Arginase, as well as methods of treatment and uses of such recombinant Arginase.

The present invention relates to novel polypeptides which are derived from Arginase1. The invention also relates to polynucleotides encoding the polypeptides. The invention also relates to compositions comprising the polypeptides and polynucleotides. The invention also concerns uses of the polypeptides, polynucleotides, and compositions.

The present disclosure provides an artificial recombinant protein for improving the performance of an active protein or polypeptide and the use thereof. The present disclosure provides a polypeptide unit (U) or a polypeptide complex unit (PU) that is very effective for prolonging the biological activity and half-life of a protein or polypeptide or improving the in-vivo and in-vitro properties of a protein or polypeptide, the polypeptide unit (U) being mainly composed of proline (P), alanine (A) and glutamic acid (E). The present disclosure also provides a biologically active fusion protein comprising the polypeptide unit (U) or the polypeptide complex unit (PU) and an active protein or polypeptide connected thereto.

Described herein are methods and compositions relating to methods of inhibiting neutrophils, e.g., inhibiting NET release or NETosis, by means of a DEspR inhibitor, e.g., an anti-DEspR antibody reagent. In some embodiments, the methods can relate to the treatment of a disease, e.g., cancer or a disease wherein neutrophils; NETs; or NETosing or NETting neutrophils contribute to pathogenesis, chronicity, or worsening of disease. In some embodiments, the DEspR inhibitor can be a bi-specific reagent or an antibody-drug conjugate.

The present invention relates to mRNAs useful in cancer therapies as well as mRNAs for use in a method for the prevention or treatment of cancer in a subject.